Related Experiment Video
Updated: Jan 31, 2026
Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
Published on: September 13, 2024
Advances in Antithrombotic Therapy
Jeffrey I Weitz1, Noel C Chan1
1From the Thrombosis and Atherosclerosis Research Institute and Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Insights
New antithrombotic therapies show promise. Combining low-dose rivaroxaban with aspirin prevents ischemic events but increases bleeding risk. Factor XI is a potential target for safer anticoagulants.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Thrombosis is a significant cause of death and disability.
- Effective antithrombotic therapies are crucial for reducing disease burden.
Purpose of the Study:
- To review recent advances in antithrombotic therapy.
- To discuss the prevention of atherothrombosis and the potential of novel anticoagulant targets.
Main Methods:
- Review of current literature on antithrombotic agents.
- Analysis of clinical trial data for rivaroxaban plus aspirin.
- Exploration of factor XI as a therapeutic target.
Main Results:
- Low-dose rivaroxaban plus aspirin is more effective than aspirin alone in preventing recurrent ischemic events in patients with atherothrombosis.
- This combination therapy increases bleeding risk, though not typically fatal.
- Factor XI has been identified as a promising target for developing safer anticoagulants.
Conclusions:
- Advances in antithrombotic therapy are improving patient outcomes.
- Balancing efficacy and bleeding risk remains a key challenge.
- Targeting factor XI offers a potential pathway to safer and more effective anticoagulation.
Abstract:
Thrombosis remains a major cause of morbidity and mortality. Consequently, advances in antithrombotic therapy are needed to reduce the disease burden. This article focuses on 2 such advances. First, the prevention of atherothrombosis in patients with coronary or peripheral artery disease, which has been enhanced by the finding that the combination of low-dose rivaroxaban plus aspirin is superior to aspirin alone for prevention of recurrent ischemic events. However, this benefit comes at the cost of increased bleeding albeit not fatal bleeding. To overcome this problem, the second advance is the identification of factor XI as a target for new anticoagulants that are potentially safer than those currently available.
Related Concept Videos
00:59Gene Therapy
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
00:56Extraction: Advanced Methods
01:26Group Therapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:22Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...